CD80
PD-L1
CD28
免疫疗法
免疫系统
T细胞
共刺激
抗原提呈细胞
效应器
化学
功能(生物学)
细胞生物学
生物
细胞毒性T细胞
免疫学
生物化学
体外
CD40
作者
Daisuke Sugiura,Takumi Maruhashi,Il‐mi Okazaki,Kenji Shimizu,Takeo K. Maeda,Tatsuya Takemoto,Taku Okazaki
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2019-04-19
卷期号:364 (6440): 558-566
被引量:293
标识
DOI:10.1126/science.aav7062
摘要
Targeted blockade of PD-1 with immune checkpoint inhibitors can activate T cells to destroy tumors. PD-1 is believed to function mainly at the effector, but not in the activation, phase of T cell responses, yet how PD-1 function is restricted at the activation stage is currently unknown. Here we demonstrate that CD80 interacts with PD-L1 in cis on antigen-presenting cells (APCs) to disrupt PD-L1/PD-1 binding. Subsequently, PD-L1 cannot engage PD-1 to inhibit T cell activation when APCs express substantial amounts of CD80. In knock-in mice in which cis-PD-L1/CD80 interactions do not occur, tumor immunity and autoimmune responses were greatly attenuated by PD-1. These findings indicate that CD80 on APCs limits the PD-1 coinhibitory signal, while promoting CD28-mediated costimulation, and highlight critical components for induction of optimal immune responses.
科研通智能强力驱动
Strongly Powered by AbleSci AI